Steve Scala
Stock Analyst at TD Cowen
(2.78)
# 1,738
Out of 5,112 analysts
32
Total ratings
74.07%
Success rate
13.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Scala
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPRX Royalty Pharma | Maintains: Buy | $42 → $45 | $38.31 | +17.46% | 2 | Dec 11, 2025 | |
| ABBV AbbVie | Maintains: Buy | $195 → $225 | $224.31 | +0.31% | 12 | Oct 7, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Hold | $53 → $59 | $53.55 | +10.18% | 3 | Oct 7, 2024 | |
| AZN AstraZeneca | Maintains: Buy | $90 → $95 | $89.86 | +5.72% | 1 | Aug 12, 2024 | |
| MRK Merck & Co. | Upgrades: Outperform | $125 → $135 | $99.18 | +36.12% | 1 | Jan 4, 2024 | |
| PFE Pfizer | Downgrades: Market Perform | $32 | $25.04 | +27.80% | 1 | Jan 4, 2024 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $430 → $500 | $1,041.79 | -52.01% | 8 | May 23, 2023 | |
| NVS Novartis AG | Downgrades: Market Perform | $110 → $105 | $135.03 | -22.24% | 4 | Feb 1, 2021 |
Royalty Pharma
Dec 11, 2025
Maintains: Buy
Price Target: $42 → $45
Current: $38.31
Upside: +17.46%
AbbVie
Oct 7, 2024
Maintains: Buy
Price Target: $195 → $225
Current: $224.31
Upside: +0.31%
Bristol-Myers Squibb Company
Oct 7, 2024
Maintains: Hold
Price Target: $53 → $59
Current: $53.55
Upside: +10.18%
AstraZeneca
Aug 12, 2024
Maintains: Buy
Price Target: $90 → $95
Current: $89.86
Upside: +5.72%
Merck & Co.
Jan 4, 2024
Upgrades: Outperform
Price Target: $125 → $135
Current: $99.18
Upside: +36.12%
Pfizer
Jan 4, 2024
Downgrades: Market Perform
Price Target: $32
Current: $25.04
Upside: +27.80%
Eli Lilly and Company
May 23, 2023
Maintains: Outperform
Price Target: $430 → $500
Current: $1,041.79
Upside: -52.01%
Novartis AG
Feb 1, 2021
Downgrades: Market Perform
Price Target: $110 → $105
Current: $135.03
Upside: -22.24%